At the news
? BULLISHIMPACT 5/10 PRESS-RELEASE filed Jun 29, 2026 at 07:00 ET
Dianthus Therapeutics initiated the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis, building on positive Phase 2 results. Top-line data expected in 2H'28; the stock may see modest positive momentum from trial advancement but major catalysts are distant.
- Phase 3 EMERGE trial initiated in ~195 AChR+ gMG patients with claseprubart 300mg Q2W or Q4W
- Primary endpoint: change from baseline in MG-ADL; top-line results expected 2H'28
- Claseprubart granted Orphan Drug Designation by FDA for MG in May 2026
- Phase 2 MaGic trial showed rapid, sustained, statistically significant improvements vs placebo
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access